In vivo enrichment of cytidine deaminase gene-modified hematopoietic cells by prolonged cytosine-arabinoside application

References

• Aiuti A, Slavin S, Aker M, Ficara F, Deola S, Mortellaro A, . Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning. Science. 2002;296:2410–3.
   PubMed Web of Science ®Google Scholar
• Boztug K, Schmidt M, Schwarzer A, Banerjee PP, Diez IA, Dewey RA, . Stem-cell gene therapy for the Wiskott–Aldrich syndrome. N Engl J Med. 2010;363:1918–27.
   PubMed Web of Science ®Google Scholar
• Hacein-Bey-Abina S, Fischer A, Cavazzana-Calvo M. Gene therapy of X-linked severe combined immunodeficiency. Int J Hematol. 2002;76:295–8.
   Google Scholar
• Ott MG, Schmidt M, Schwarzwaelder K, Stein S, Siler U, Koehl U, . Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1. Nat Med. 2006;12:401–9.
   PubMed Web of Science ®Google Scholar
• Neff T, Beard BC, Kiem HP. Survival of the fittest: in vivo selection and stem cell gene therapy. Blood. 2006;107:1751–60.
   PubMed Web of Science ®Google Scholar
• Flasshove M, Moritz T, Bardenheuer W, Seeber S. Hematoprotection by transfer of drug-resistance genes. Acta Haematol. 2003;110:93–106.
   Google Scholar
• Trobridge GD, Kiem HP. Large animal models of hematopoietic stem cell gene therapy. Gene Ther. 2010;17:939–48.
   PubMed Web of Science ®Google Scholar
• Moritz T, Williams DA. Marrow protection - transduction of hematopoietic cells with drug resistance genes. Cytotherapy. 2001;3:67–84.
   PubMed Web of Science ®Google Scholar
• Allay JA, Persons DA, Galipeau J, Riberdy JM, Ashmun RA, Blakley RL, . In vivo selection of retrovirally transduced hematopoietic stem cells. Nat Med. 1998;4:1136–43.
   PubMed Web of Science ®Google Scholar
• Persons DA, Allay JA, Bonifacino A, Lu T, Agricola B, Metzger ME, . Transient in vivo selection of transduced peripheral blood cells using antifolate drug selection in rhesus macaques that received transplants with hematopoietic stem cells expressing dihydrofolate reductase vectors. Blood. 2004;103:796–803.
   PubMed Web of Science ®Google Scholar
• Abonour R, Williams DA, Einhorn L, Hall KM, Chen J, Coffman J, . Efficient retrovirus-mediated transfer of the multidrug resistance 1 gene into autologous human long-term repopulating hematopoietic stem cells. Nat Med. 2000;6:652–8.
   PubMed Web of Science ®Google Scholar
• Cowan KH, Moscow JA, Huang H, Zujewski JA, O'Shaughnessy J, Sorrentino B, . Paclitaxel chemotherapy after autologous stem-cell transplantation and engraftment of hematopoietic cells transduced with a retrovirus containing the multidrug resistance complementary DNA (MDR1) in metastatic breast cancer patients. Clin Cancer Res. 1999; 5:1619–28.
   PubMed Web of Science ®Google Scholar
• Moscow JA, Huang H, Carter C, Hines K, Zujewski J, Cusack G, . Engraftment of MDR1 and NeoR gene-transduced hematopoietic cells after breast cancer chemotherapy. Blood. 1999;94:52–61.
   PubMed Web of Science ®Google Scholar
• Beard BC, Trobridge GD, Ironside C, McCune JS, Adair JE, Kiem HP. Efficient and stable MGMT-mediated selection of long-term repopulating stem cells in nonhuman primates. J Clin Invest. 2010;120:2345–54.
   PubMed Web of Science ®Google Scholar
• Larochelle A, Choi U, Shou Y, Naumann N, Loktionova NA, Clevenger JR, . In vivo selection of hematopoietic progenitor cells and temozolomide dose intensification in rhesus macaques through lentiviral transduction with a drug resistance gene. J Clin Invest. 2009;119:1952–63.
   Google Scholar
• Milsom MD, Williams DA. Live and let die: in vivo selection of gene-modified hematopoietic stem cells via MGMT-mediated chemoprotection. DNA Repair (Amst). 2007;6: 1210–21.
   Google Scholar
• Jansen M, Sorg UR, Ragg S, Flasshove M, Seeber S, Williams DA, . Hematoprotection and enrichment of transduced cells in vivo after gene transfer of MGMT(P140K) into hematopoietic stem cells. Cancer Gene Ther. 2002;9:737–46.
   PubMed Web of Science ®Google Scholar
• Ragg S, Xu-Welliver M, Bailey J, D'Souza M, Cooper R, Chandra S, . Direct reversal of DNA damage by mutant methyltransferase protein protects mice against dose-intensified chemotherapy and leads to in vivo selection of hematopoietic stem cells. Cancer Res. 2000;60:5187–95.
   PubMed Web of Science ®Google Scholar
• Geiger H, Schleimer D, Nattamai KJ, Dannenmann SR, Davies SM, Weiss BD. Mutagenic potential of temozolomide in bone marrow cells in vivo. Blood. 2006;107:3010–1.
   PubMed Web of Science ®Google Scholar
• Schmitz N, Diehl V. Carmustine and the lungs. Lancet. 1997;349:1712–3.
   Google Scholar
• Bardenheuer W, Lehmberg K, Rattmann I, Brueckner A, Schneider A, Sorg UR, . Resistance to cytarabine and gemcitabine and in vitro selection of transduced cells after retroviral expression of cytidine deaminase in human hematopoietic progenitor cells. Leukemia. 2005;19:2281–8.
   PubMed Web of Science ®Google Scholar
• Momparler RL, Eliopoulos N, Bovenzi V, Letourneau S, Greenbaum M, Cournoyer D. Resistance to cytosine arabinoside by retrovirally mediated gene transfer of human cytidine deaminase into murine fibroblast and hematopoietic cells. Cancer Gene Ther. 1996;3:331–8.
   Google Scholar
• Neff T, Blau CA. Forced expression of cytidine deaminase confers resistance to cytosine arabinoside and gemcitabine. Exp Hematol. 1996;24:1340–6.
   PubMed Web of Science ®Google Scholar
• Rattmann I, Kleff V, Sorg UR, Bardenheuer W, Brueckner A, Hilger RA, . Gene transfer of cytidine deaminase protects myelopoiesis from cytidine analogs in an in vivo murine transplant model. Blood. 2006;108:2965–71.
   PubMed Web of Science ®Google Scholar
• Eliopoulos N, Al-Khaldi A, Beausejour CM, Momparler RL, Momparler LF, Galipeau J. Human cytidine deaminase as an ex vivo drug selectable marker in gene-modified primary bone marrow stromal cells. Gene Ther. 2002;9:452–62.
   PubMed Web of Science ®Google Scholar
• Leach WB, Laster WR Jr, Mayo JG, Griswold DP Jr, Schabel FM Jr. Toxicity studies in mice treated with 1-beta-d-arabinofuranosylcytosine (ara-C). Cancer Res. 1969;29: 529–35.
   Google Scholar
• Ubezio P, Tagliabue G, Schechter B, Agur Z. Increasing 1-beta-d-arabinofuranosylcytosine efficacy by scheduled dosing intervals based on direct measurements of bone marrow cell kinetics. Cancer Res. 1994;54:6446–51.
   PubMed Web of Science ®Google Scholar
• Dunlop DJ, Wright EG, Lorimore S, Graham GJ, Holyoake T, Kerr DJ, . Demonstration of stem cell inhibition and myeloprotective effects of SCI/rhMIP1 alpha in vivo. Blood. 1992;79:2221–5.
   PubMed Web of Science ®Google Scholar
• Kiel MJ, Yilmaz OH, Iwashita T, Terhorst C, Morrison SJ. SLAM family receptors distinguish hematopoietic stem and progenitor cells and reveal endothelial niches for stem cells. Cell. 2005;121:1109–21.
   PubMed Web of Science ®Google Scholar
• Randall TD, Weissman IL. Phenotypic and functional changes induced at the clonal level in hematopoietic stem cells after 5-fluorouracil treatment. Blood. 1997;89:3596–606.
   PubMed Web of Science ®Google Scholar
• Toy G, Austin WR, Liao HI, Cheng D, Singh A, Campbell DO, . Requirement for deoxycytidine kinase in T and B lymphocyte development. Proc Natl Acad Sci USA. 2010; 107:5551–6.
   PubMed Web of Science ®Google Scholar
• Powell BL, Capizzi RL, Muss HB, Bearden JD, Lyerly ES, Rosenbaum DL, . Low-dose ara-C therapy for acute myelogenous leukemia in elderly patients. Leukemia. 1989;3: 23–8.
   PubMed Web of Science ®Google Scholar
• Stentoft J. The toxicity of cytarabine. Drug Saf. 1990;5:7–27.
   PubMed Web of Science ®Google Scholar
• Chhikara BS, Parang K. Development of cytarabine prodrugs and delivery systems for leukemia treatment. Expert Opin Drug Deliv. 2010;7:1399–414.
   PubMed Web of Science ®Google Scholar
• Elli M, Aydin O, Bilge S, Bozkurt A, Dagdemir A, Pinarli FG, . Protective effect of vitamin A on ARA-C induced intestinal damage in mice. Tumori. 2009;95:87–90.
   Google Scholar
• Morrison SJ, Wright DE, Weissman IL. Cyclophosphamide/granulocyte colony-stimulating factor induces hematopoietic stem cells to proliferate prior to mobilization. Proc Natl Acad Sci USA. 1997;94:1908–13.
   PubMed Web of Science ®Google Scholar
• Wilson A, Laurenti E, Oser G, van der Wath RC, Blanco-Bose W, Jaworski M, . Hematopoietic stem cells reversibly switch from dormancy to self-renewal during homeostasis and repair. Cell. 2008;135:1118–29.
   PubMed Web of Science ®Google Scholar
• Bodine DM, Orlic D, Birkett NC, Seidel NE, Zsebo KM. Stem cell factor increases colony-forming unit-spleen number in vitro in synergy with interleukin-6, and in vivo in Sl/Sld mice as a single factor. Blood. 1992;79:913–9.
   PubMed Web of Science ®Google Scholar
• Essers MA, Offner S, Blanco-Bose WE, Waibler Z, Kalinke U, Duchosal MA, . IFNalpha activates dormant haematopoietic stem cells in vivo. Nature. 2009;458:904–8.
   PubMed Web of Science ®Google Scholar
• van Pelt K, de Haan G, Vellenga E, Daenen SM. Administration of low-dose cytarabine results in immediate S-phase arrest and subsequent activation of cell cycling in murine stem cells. Exp Hematol. 2005;33:226–31.
   Google Scholar
• Agur Z, Arnon R, Schechter B. Effect of the dosing interval on myelotoxicity and survival in mice treated by cytarabine. Eur J Cancer. 1992;28A:1085–90.
   PubMed Web of Science ®Google Scholar
• Gardner RV, Lerner C, Astle CM, Harrison DE. Assessing permanent damage to primitive hematopoietic stem cells after chemotherapy using the competitive repopulation assay. Cancer Chemother Pharmacol. 1993;32:450–4.
   PubMedGoogle Scholar
• Kleff V, Sorg UR, Bury C, Suzuki T, Rattmann I, Jerabek-Willemsen M, . Gene therapy of beta(c)-deficient pulmonary alveolar proteinosis (beta(c)-PAP): studies in a murine in vivo model. Mol Ther. 2008;16:757–64.
   PubMed Web of Science ®Google Scholar
• Luskey BD, Rosenblatt M, Zsebo K, Williams DA. Stem cell factor, interleukin-3, and interleukin-6 promote retroviral-mediated gene transfer into murine hematopoietic stem cells. Blood. 1992;80:396–402.
   PubMed Web of Science ®Google Scholar
• Ailles L, Schmidt M, Santoni de Sio FR, Glimm H, Cavalieri S, Bruno S, . Molecular evidence of lentiviral vector-mediated gene transfer into human self-renewing, multi-potent, long-term NOD/SCID repopulating hematopoietic cells. Mol Ther. 2002;6:615–26.
   PubMed Web of Science ®Google Scholar
• Horn PA, Keyser KA, Peterson LJ, Neff T, Thomasson BM, Thompson J, . Efficient lentiviral gene transfer to canine repopulating cells using an overnight transduction protocol. Blood. 2004;103:3710–6.
   PubMed Web of Science ®Google Scholar
• Laufs S, Guenechea G, Gonzalez-Murillo A, Zsuzsanna Nagy K, Luz Lozano M, del Val C, . Lentiviral vector integration sites in human NOD/SCID repopulating cells. J Gene Med. 2006;8:1197–207.
   PubMed Web of Science ®Google Scholar
• Sangiolo D, Lesnikova M, Nash RA, Jensen MC, Nikitine A, Kiem HP, . Lentiviral vector conferring resistance to mycophenolate mofetil and sensitivity to ganciclovir for in vivo T-cell selection. Gene Ther. 2007;14:1549–54.
   PubMed Web of Science ®Google Scholar
• Mailly L, Leboeuf C, Tiberghien P, Baumert T, Robinet E. Genetically engineered T-cells expressing a ganciclovir-sensitive HSV-tk suicide gene for the prevention of GvHD. Curr Opin Investig Drugs. 2010;11:559–70.
   PubMed Web of Science ®Google Scholar
• Modlich U, Kustikova OS, Schmidt M, Rudolph C, Meyer J, Li Z, . Leukemias following retroviral transfer of multidrug resistance 1 (MDR1) are driven by combinatorial insertional mutagenesis. Blood. 2005;105:4235–46.
   PubMed Web of Science ®Google Scholar
• Weisburger EK. Bioassay program for carcinogenic hazards of cancer chemotherapeutic agents. Cancer. 1977;40: 1935–49.
   PubMed Web of Science ®Google Scholar